CA3111903A1 - Method for selecting neoepitopes - Google Patents
Method for selecting neoepitopes Download PDFInfo
- Publication number
- CA3111903A1 CA3111903A1 CA3111903A CA3111903A CA3111903A1 CA 3111903 A1 CA3111903 A1 CA 3111903A1 CA 3111903 A CA3111903 A CA 3111903A CA 3111903 A CA3111903 A CA 3111903A CA 3111903 A1 CA3111903 A1 CA 3111903A1
- Authority
- CA
- Canada
- Prior art keywords
- neoepitopes
- mhc
- binding
- score
- minimal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18197172.2 | 2018-09-27 | ||
| EP18197172 | 2018-09-27 | ||
| PCT/EP2019/076210 WO2020065023A1 (en) | 2018-09-27 | 2019-09-27 | Method for selecting neoepitopes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3111903A1 true CA3111903A1 (en) | 2020-04-02 |
Family
ID=63794302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3111903A Pending CA3111903A1 (en) | 2018-09-27 | 2019-09-27 | Method for selecting neoepitopes |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12462898B2 (https=) |
| EP (1) | EP3856957A1 (https=) |
| JP (1) | JP7585195B2 (https=) |
| KR (1) | KR102902460B1 (https=) |
| CN (1) | CN112771214B (https=) |
| AU (1) | AU2019346023B2 (https=) |
| BR (1) | BR112021005702A8 (https=) |
| CA (1) | CA3111903A1 (https=) |
| IL (1) | IL281771B2 (https=) |
| MX (1) | MX2021003654A (https=) |
| SG (1) | SG11202101965QA (https=) |
| WO (1) | WO2020065023A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020221783A1 (en) * | 2019-04-29 | 2020-11-05 | Vaccibody As | Methods for pre-selection of neoepitopes |
| US20230197192A1 (en) * | 2020-11-06 | 2023-06-22 | Amazon Technologies, Inc. | Selecting neoantigens for personalized cancer vaccine |
| GB202102606D0 (en) * | 2021-02-24 | 2021-04-07 | Univ Oxford Innovation Ltd | Treatment of ovarian cancer minimal residual disease |
| IL305777A (en) | 2021-03-26 | 2023-11-01 | Nykode Therapeutics ASA | Medical combination for cancer treatment |
| WO2022238420A2 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Co-expression of constructs and immunostimulatory compounds |
| WO2022238381A2 (en) | 2021-05-10 | 2022-11-17 | Nykode Therapeutics ASA | Immunotherapy constructs for treatment of disease |
| WO2023244997A1 (en) * | 2022-06-13 | 2023-12-21 | The University Of North Carolina At Chapel Hill | Compositions and methods for inducing anticancer immunity |
| EP4608436A1 (en) | 2022-10-25 | 2025-09-03 | Nykode Therapeutics ASA | Constructs and their use |
| KR102857635B1 (ko) * | 2022-11-08 | 2025-09-10 | 인바이츠지노믹스 주식회사 | 면역원성이 높은 유사체를 디자인하는 방법 및 이를 이용한 장치 |
| WO2024100196A1 (en) | 2022-11-09 | 2024-05-16 | Nykode Therapeutics ASA | Co-expression of constructs and polypeptides |
| WO2024216073A1 (en) * | 2023-04-14 | 2024-10-17 | The Trustees Of Columbia University In The City Of New York | Engineered microbes comprising tumor neoantigen vectors for cancer immunotherapy |
| US20250232833A1 (en) * | 2024-01-13 | 2025-07-17 | Noergaard Anders Kaare | Cyclin D1 Based Cancer Vaccine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012029066A2 (pt) | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | composições e processos de identificação de neoantígenos específicos de tumor. |
| HRP20211595T1 (hr) | 2011-05-24 | 2022-01-21 | BioNTech SE | Individualizirana cjepiva protiv raka |
| WO2014082729A1 (en) | 2012-11-28 | 2014-06-05 | Biontech Ag | Individualized vaccines for cancer |
| CN118750591A (zh) | 2013-04-07 | 2024-10-11 | 博德研究所 | 用于个性化瘤形成疫苗的组合物和方法 |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| JP6558699B2 (ja) | 2013-10-01 | 2019-08-14 | 国立大学法人三重大学 | 抗原提示を促進するエピトープ間配列を含むｔ細胞誘導ワクチン |
| US11186640B2 (en) | 2014-07-31 | 2021-11-30 | The University Of Western Australia | Method for the identification of immunotherapy-drug combinations using a network approach |
| EP3193892A4 (en) | 2014-09-14 | 2018-09-12 | Washington University | Personalized cancer vaccines and methods therefor |
| US10317402B2 (en) | 2014-12-03 | 2019-06-11 | Verik Bio, Inc. | Identification, selection and use of high curative potential T cell epitopes |
| WO2016128060A1 (en) * | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| CA2988388C (en) * | 2015-04-23 | 2022-11-22 | Nantomics, Llc | Cancer neoepitopes |
| SG10201912485PA (en) * | 2015-05-13 | 2020-02-27 | Agenus Inc | Vaccines for treatment and prevention of cancer |
| EP3323070B1 (en) * | 2015-07-14 | 2024-05-08 | Personal Genome Diagnostics Inc. | Neoantigen analysis |
| RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| WO2018136664A1 (en) * | 2017-01-18 | 2018-07-26 | Ichan School Of Medicine At Mount Sinai | Neoantigens and uses thereof for treating cancer |
| EP3678699A1 (en) | 2017-09-07 | 2020-07-15 | University Of Oslo | Vaccine molecules |
-
2019
- 2019-09-27 CN CN201980063254.9A patent/CN112771214B/zh active Active
- 2019-09-27 JP JP2021517009A patent/JP7585195B2/ja active Active
- 2019-09-27 BR BR112021005702A patent/BR112021005702A8/pt unknown
- 2019-09-27 WO PCT/EP2019/076210 patent/WO2020065023A1/en not_active Ceased
- 2019-09-27 EP EP19773458.5A patent/EP3856957A1/en active Pending
- 2019-09-27 AU AU2019346023A patent/AU2019346023B2/en active Active
- 2019-09-27 KR KR1020217012734A patent/KR102902460B1/ko active Active
- 2019-09-27 CA CA3111903A patent/CA3111903A1/en active Pending
- 2019-09-27 US US17/279,946 patent/US12462898B2/en active Active
- 2019-09-27 MX MX2021003654A patent/MX2021003654A/es unknown
- 2019-09-27 SG SG11202101965QA patent/SG11202101965QA/en unknown
- 2019-09-27 IL IL281771A patent/IL281771B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022502416A (ja) | 2022-01-11 |
| BR112021005702A2 (pt) | 2021-06-22 |
| IL281771B1 (en) | 2025-04-01 |
| MX2021003654A (es) | 2021-05-28 |
| AU2019346023A1 (en) | 2021-03-25 |
| BR112021005702A8 (pt) | 2022-11-08 |
| US12462898B2 (en) | 2025-11-04 |
| WO2020065023A1 (en) | 2020-04-02 |
| US20210388438A1 (en) | 2021-12-16 |
| JP7585195B2 (ja) | 2024-11-18 |
| CN112771214A (zh) | 2021-05-07 |
| KR102902460B1 (ko) | 2025-12-19 |
| EP3856957A1 (en) | 2021-08-04 |
| IL281771B2 (en) | 2025-08-01 |
| CN112771214B (zh) | 2025-06-13 |
| KR20210065171A (ko) | 2021-06-03 |
| AU2019346023B2 (en) | 2024-12-12 |
| SG11202101965QA (en) | 2021-04-29 |
| IL281771A (en) | 2021-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12462898B2 (en) | Method for selecting neoepitopes | |
| JP7651623B2 (ja) | 新生抗原の特定、製造、及び使用 | |
| JP7530455B2 (ja) | 新生抗原の特定、製造、及び使用 | |
| CN104662171B (zh) | 个性化癌症疫苗和过继免疫细胞治疗 | |
| WO2020221783A1 (en) | Methods for pre-selection of neoepitopes | |
| US20170212984A1 (en) | Neoantigen Identification, Manufacture, and Use | |
| TWI672503B (zh) | 致免疫性之癌症特異抗原決定位的排名系統 | |
| KR20190027832A (ko) | 향상된 효능을 갖는 치료를 위한 질병-특이적 표적으로서 네오에피토프의 선택 | |
| Castro et al. | Neoantigen controversies | |
| TW202517684A (zh) | 選擇新抗原的方法、癌症疫苗組成物及其製備方法 | |
| US20240024439A1 (en) | Administration of anti-tumor vaccines | |
| RU2826184C2 (ru) | Способ отбора неоэпитопов | |
| HK40013532B (zh) | 致免疫性的癌症特异抗原决定位的排名系统 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240821 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240821 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240821 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240916 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240916 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241120 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241203 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241203 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250415 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250910 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250910 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260205 |